Inivata initiates clinical trial of ctDNA in non-small-cell lung cancer

Global clinical cancer genomics company Inivata has announced the initiation of its US clinical validation study (INI-001) of a new approach to circulating tumour DNA (ctDNA) in non-small-cell lung cancer (NSCLC).

Source: Drug Development Technology - October 12, 2016 Category: Pharmaceuticals Source Type: news